

Maryland



Maryland - HB 903

Sponsor: Delegate Dan Cox (R)

Actions: 03/14/2022 Hearing scheduled
02/07/2022 Introduced; referred to the House Health and Government Operations Committee

Summary: Summary for 2/7/2022 Version

This measure relates to ensuring the provision or continuation of life-sustaining care. The measure also relates to utilization review management and decisions.

This measure applies to insurers.

This measure requires health care providers or health care institutions to ensure the provision or continuation of the directed life-sustaining care if patients, patients' families, or patients' advance directives direct the provision or opposes the withdrawal of life-sustaining care that has a significant possibility of sustaining the life of the patient. The measure requires any transfer of a patient to be done promptly on eh agreement by the receiving Health Care Provider or Health Care Institution to admit the patient. The measure prohibits agencies from developing or using dollars per quality-adjusted life-year or a similar measure that discounts the value of a life based on an individual's disability and using dollars per quality-adjusted life hear or similar measure as a threshold to make coverage reimbursement, incentive program, or utilization management decisions.

This measure requires agencies proposing new utilization management measures to post the proposed measure and the rationale for the proposed measure. The measure requires agencies making decisions on utilization management measures, coverage, reimbursement, or incentive programs to consult with organizations representing patients with disabilities, self-advocacy organizations, organizations representing patients, and organizations who advocate for the rights of patients. The measure requires agencies making decisions on utilization management measures to ensure that a process is in place to ensure robust stakeholder engagement and full transparency regarding the provision of any research and analysis relied on for decision making that would impact access to health care treatments and services by patient groups.

This measure takes effect on October 1, 2022.

Bill Links [2/7/2022 Version](#)



Maryland - HB 961

Sponsor: Delegate Ken Kerr (D)

Actions: 02/25/2022 Hearing held
02/10/2022 Introduced; Referred to House Health and Government Operations Committee

Summary: Summary for 2/10/2022 Version

This measure requires a collaboration agreement between physicians and physician assistants to replace delegation agreements. This bills creates the criteria for the collaboration agreements and submission date to the State Board of Physicians.

This measure applies to Physicians and Physician Assistants. This measure requires a physician assistant to practice under a collaboration agreement with a signing physician rather than under a delegation agreement with a primary supervising physician.

This measure requires a physician assistant to submit a collaboration agreement to the State Board of Physicians before September 30, 2022. This measure changes the scope of practice for a licensed physician assistant to acts authorized by a collaboration agreement. This measure repeals the provisions of law governing the delegation of prescribing, dispensing, and administering controlled dangerous substances, prescription drugs, and medical devices and delegation agreements.

This measure takes effect on October 1, 2022

Bill Links [2/10/2022 Version](#)



Maryland - HB 972

Sponsor: Delegate Ariana Kelly (D)

Actions: 03/11/2022 Hearing Scheduled
03/10/2022 Hearing Held
03/04/2022 Hearing Canceled
03/03/2022 Hearing held
02/24/2022 Hearing Held
02/10/2022 Introduced; Referred to House Health and Government Operations Committee

Summary: Summary for 2/10/2022 Version

This measure eliminates the requirement for a certificate of need continuing care agreements, including continuing care at home agreements.

This measure amends the definition of "health care facility", for the purpose of providing exemption from the certificate of need requirement, so that it does not include facilities that are for the exclusive use of the provider's subscribers who have executed continuing care agreements, including continuing care at home agreements.

This measure takes effect October 1, 2022.

Bill Links [2/10/2022 Version](#)



Maryland - SB 305

Sponsor: Senator Clarence Lam (D)

Actions: 02/10/2022 Hearing held
01/20/2022 Introduced; Referred to Senate Education, Health, and Environmental Affairs Committee

Summary: Summary for 1/20/2022 Version

This measure transfers oversight for the inspection of the offices of licensed dispensing physicians from the Office of Controlled Substances Administration to the State Board of Physicians.

This measure alters the circumstances under which a physician may dispense drugs or devices.

This measure transfers oversight for the inspection of the offices of licensed dispensing physicians from the Office of Controlled Substances Administration to the State Board of Physicians.

Under this measure, a licensed physician may personally prepare and dispense prescriptions only if:

- 1) The physician: i. Has an active license in good standing; ii. Has applied to the board for a dispensing permit; iii. Has paid a fee determined by the board to produce funds to approximate but not exceed the documented costs to the board for conducting inspections of dispensing permit holders; iv. Has demonstrated to the satisfaction of the board that the dispensing of prescription drugs or devices by the physician is in the public interest; v. Has received a dispensing permit from the board; vi. Has a sign conspicuously positioned and readable regarding the process for resolving incorrectly filled prescriptions or includes written information regarding the process with each prescription dispensed.
- 2) The individual for whom the drug or device is prescribed is a patient of i. The prescribing physician; ii. A physician assistant; iii. a nurse practitioner.
- 3) The physician does not have a substantial financial interest in a pharmacy.
- 4) The physician: i. Complies with the dispensing and labeling requirements of this title, title 12 of this article, and the Board's regulations; ii. Records the dispensing of the prescription drug or device on the patient's chart; iii. Provides the patient with a written prescription, maintains prescription files and maintains a separate file for Schedule II prescriptions; iv. Does not direct patients to a single pharmacist or pharmacy; v. Does not receive remuneration for referring patients to a pharmacist or pharmacy; vi. Complies with the child-resistant packaging requirements regarding prescription drugs; vii. Complies with drug recalls; viii. Maintains biennial inventories and complies with any other federal and state record-keeping requirements relating to controlled dangerous substances; ix. Purchases prescription drugs from a pharmacy or wholesale distributor that holds a permit issued by the state board of pharmacy, as verified by the state board of pharmacy; x. Complies with the continuing education requirements relating to the preparing and dispensing of prescription drugs as provided for in the regulations adopted by the Board.

This measure takes effect on October 1st, 2022.

Bill Links [1/20/2022 Version](#)



Maryland - SB 513

Sponsor: Senator Adelaide Eckardt (R)

Actions: 03/11/2022 Passed Senate; Referred to House Health and Government Operations
03/07/2022 Voting Session held; Amended; Passed committee
03/03/2022 Hearing Held
02/10/2022 Hearing Held
01/28/2022 Introduced; Referred to the Senate Education, Health, and Environmental Affairs Committee

Summary: Summary for 3/7/2022 Version

This measure defines "clinical nurse specialist" for the purpose of giving authorization to prescribe drugs and durable medical equipment under the scope of practice for a clinical nurse specialist.

This measure defines "clinical nurse specialist" to mean an individual who is licensed by the board to practice registered nursing; certified by the board to practice as a clinical nurse specialist, and authorized to prescribe drugs and durable medical equipment under regulations adopted by the board.

This measure defines "practice as a clinical nurse specialist" to mean to provide direct care to patients with complex needs; act as a consultant to another health care provider as needed; conduct health-related research and provide education and guidance for staff nurses. This would include ordering, performing, and interpreting lab test, ordering diagnostic tests and using the findings or results in the care of patients, prescribing drugs and durable medical equipment, ordering home health and hospice care, and initiating and monitoring appropriate therapies or treatments.

This measure takes effect on October 1, 2022.

Bill Links [3/7/2022 Version](#)
[1/28/2022 Version](#)



Maryland - SB 804

Sponsor: Senator Pamela Beidle (D)

Actions: 03/10/2022 Hearing Held
02/07/2022 Introduced; Referred to Senate Finance Committee

Summary: Summary for 2/7/2022 Version

This measure eliminates the requirement for a certificate of need continuing care agreements, including continuing care at home agreements.

This measure amends the definition of "health care facility", for the purpose of providing exemption from the certificate of need requirement, so that it does not include facilities that are for the exclusive

use of the provider's subscribers who have executed continuing care agreements, including continuing care *at home* agreements.

This measure takes effect October 1, 2022.

Bill Links [2/7/2022 Version](#)